Chapter 6
A tissue construct is not made in one step. It is printed, cross-linked, seeded, perfused, vascularized and matured, and each stage leaves the cells in a state that the next stage must tolerate. Phase 3 of WIA-BIO-006 specifies these protocols as one chain: bioprinting, bioreactor operation, vascularization, cross-linking and decellularization, and cell seeding. Each protocol defines its own operating window and the conditions under which a construct may move on. The hand-off rules, not any single parameter, are what make a laboratory procedure reproducible by someone else.
The first decision in the chain is the printing modality, because it fixes the resolution, the cell load and the stresses the cells will carry into the bioreactor. The standard describes three modalities, each with a calibration window:
| Modality | Principle | Key window | Cell viability | Trade-off |
|---|---|---|---|---|
| Extrusion | Pneumatic or mechanical extrusion of bioink | 10–200 kPa; nozzle 100–1000 μm; 5–50 mm/s; 4–37 °C | Post-print minimum 80%, target above 90% | High cell density and multiple materials, but lower resolution and shear stress on cells |
| Inkjet | Thermal or piezoelectric droplets | 1–300 pL; 1–10 kHz; 3–12 mPa·s | Above 85% | High speed and resolution (20–100 μm), but a narrow viscosity range |
| Laser-assisted | Laser-induced forward transfer (LIFT) | 532–1064 nm; 10–100 ns; 1–100 μJ/pulse | Above 95% | Resolution below 10 μm and no nozzle clogging, but high cost, complex setup and low throughput |
The three modalities follow analogous control-loop structures: a prepared bioink, a calibrated deposition mechanism, monitoring during the print, and post-print stabilization. Only the calibration windows differ. This shared structure lets a downstream bioreactor or seeding protocol accept constructs from any modality without being rewritten.
The technical core of Phase 3 is the physical and biological envelope inside which each protocol runs. The two subsections below follow the construct from the printer to the bioreactor.
A bioink has to flow through a nozzle and then hold its shape. The standard expresses this as rheological requirements for cell-laden hydrogels:
Viscosity (η): 30-6000 mPa·s
Shear-thinning: Yes
Storage modulus (G'): 100-10,000 Pa
Loss modulus (G"): 10-1,000 Pa
G' > G" (gel-like behavior)Shear-thinning means the ink thins under the stress inside the nozzle, which eases extrusion and limits the force on cells. The requirement that the storage modulus exceed the loss modulus means the deposited filament behaves as a gel and keeps its shape under the next layer. A typical formulation combines a polymer base (gelatin, alginate, collagen or hyaluronic acid), a cross-linker (Ca²⁺, 405 nm light or temperature), cells at 10⁶–10⁸ cells/mL, and optionally growth factors such as VEGF, BMP or FGF. The alternative is a decellularized ECM bioink. Tissue is decellularized with SDS or Triton X-100, solubilized with pepsin at pH 2–3, neutralized to pH 7.4, and only then loaded with cells at 10⁶–10⁷ cells/mL. The ink keeps tissue-specific biochemical cues and natural architecture, which is why it is chosen when cell function matters more than printability.
The printing protocol has three phases. Pre-print preparation turns a CAD model (an STL file) into layers, generates G-code toolpaths, mixes cells with the hydrogel, calibrates pressure and temperature, and loads cartridges under sterile conditions. Printing initializes the system with UV sterilization, then runs within these windows:
Pressure: 20-100 kPa
Speed: 10-30 mm/s
Temperature: 15-25°CThe operator primes the nozzle to remove air bubbles and prints the first layer with extra care, because adhesion there decides whether the rest of the construct survives. Layers continue under camera monitoring, with cross-linking applied if needed. Post-print processing then stabilizes the construct. The standard gives three cross-linking routes:
The exposure time and photoinitiator level pull in opposite directions. Longer, stronger exposure gives a stiffer gel but costs more viability, so the 80% minimum and 90% target for post-print viability act as a check on the cross-linking choice. Print accuracy is scored separately, as dimensional fidelity:
F = (1 - |D_actual - D_design| / D_design) × 100%
Target: F > 90%For decellularized tissue the quality check is residual DNA. The literature conventionally cites a target below 50 ng/mg dry tissue, after DNase/RNase digestion. The check also covers retention of glycosaminoglycans (GAG) and collagen, since a thorough decellularization that strips the matrix would defeat the purpose of using ECM.
After printing and cross-linking, the construct matures for one to four weeks in a bioreactor. The standard defines four reactor types, and each one matches a different mechanical or transport need.
Culture conditions hold the cells at 37 °C ± 0.5 °C and pH 7.2–7.6, using CO₂ regulation at 5–10%, HEPES buffer and automated pH monitoring. Oxygen tension is tissue-dependent: bone 5–10%, cartilage 2–5%, liver 10–20%, cardiac 5–15%. The low range is deliberate for some tissues. Hypoxia supports stem-cell maintenance and chondrogenesis and stimulates angiogenesis. Glucose consumption is modelled as r_glucose = k × C_cells, so medium exchange is scheduled from the cell concentration instead of a fixed calendar.
Real-time sensors close the loop on these conditions. The standard lists the following:
| Parameter | Sensor | Range | Accuracy |
|---|---|---|---|
| Temperature | RTD | 20–45 °C | ±0.1 °C |
| pH | Glass electrode | 6–8 | ±0.05 |
| Dissolved O₂ | Optical | 0–100% | ±2% |
| Glucose | Enzymatic | 0–25 mM | ±0.5 mM |
| Lactate | Enzymatic | 0–20 mM | ±0.5 mM |
Feedback uses a PID controller, u(t) = K_p·e(t) + K_i·∫e(t)dt + K_d·de(t)/dt, with the error defined as setpoint minus measured value. The protocol includes gain selection per setpoint, fault-tree analysis for medium loss, and an alarm escalation matrix. The matrix separates class-A systems (clinical-grade) from class-B systems (industrial), so a pH excursion does not trigger the same response in both.
The standard publishes no market figures, so this section limits itself to the trade-offs it does state. Printing hardware ranges from cost-effective extrusion and low-cost inkjet to high-cost, low-throughput laser-assisted systems. A laboratory therefore chooses a modality by balancing cell density, resolution and budget. The same applies to culture media. The standard's reference formulation is a DMEM/F12 base with 10% FBS, or a serum-free alternative, plus 1% penicillin/streptomycin and tissue-specific growth factors. Serum-free choices matter most where clinical-grade work is planned, since that is the setting where the class-A alarm matrix and ISO 5 sterility requirements apply.
Because the protocols set out an explicit operating window for each stage, a research group, a contract manufacturer and a clinical site can describe the same construct in the same terms. The standard intends this shared description to reduce the cost of moving a process between them.
Applications split by tissue type, and the protocol that dominates differs for each. Load-bearing tissues such as bone, cartilage, ligament and tendon depend on the compression bioreactor. Hepatic and cartilage constructs use the rotating-wall vessel. Any construct thicker than the diffusion range depends on vascularization, which is the largest protocol chapter in Phase 3, followed by cell seeding.
Oxygen diffuses only about 100–200 μm into tissue, so constructs thicker than about 2 mm need blood vessels for oxygen delivery, nutrient supply, waste removal and host integration. The standard offers three routes.
Co-culture. Parenchymal cells are seeded on day 0. Endothelial cells follow on days 3–7 at a ratio between 10:1 and 5:1 (parenchymal to endothelial). The culture then runs 7–14 days with VEGF (10–50 ng/mL), bFGF (5–20 ng/mL) and Ang-1 (50–100 ng/mL). Network formation is verified by CD31 immunostaining.
Microfluidic channels. A branched network is formed with channels 50–500 μm in diameter and 200–1000 μm apart, using sacrificial Pluronic F127 or gelatin templates, coaxial printing or laser ablation. After printing, endothelial cells are seeded into the channels. The bioreactor rotates for 24–48 hours so the cells cover the lumen evenly, flow starts afterward, and maturation takes 5–10 days. Starting flow only after the cells have attached is the key ordering rule.
Sustained growth-factor delivery. Release is modelled as M_t / M_∞ = 1 − exp(−kt), where k is the release rate constant. Delivery systems include PLGA microspheres, hydrogel encapsulation and heparin affinity binding.
In vivo, an arteriovenous loop is built from the femoral artery and vein, embedded in the construct and implanted subcutaneously for 2–4 weeks. The construct is then transferred to the target site. The benefits are rapid vascularization, mature vessels and functional perfusion. The alternative is host-mediated angiogenesis: the construct is implanted with VEGF (0.1–10 μg), bFGF or PDGF, and host vessels infiltrate over 2–6 weeks.
Seeding determines how many cells end up where they are needed, so the standard compares four methods with expected efficiencies:
| Method | Procedure | Expected efficiency |
|---|---|---|
| Static | 10⁶ cells/mL pipetted onto the scaffold, 2–4 h attachment, optional flip for top/bottom uniformity | 20–50% |
| Dynamic spinner | 50 rpm for 4–8 h | 40–70% |
| Vacuum | 50–100 kPa for 5–10 min drives cells into pores | 60–90% |
| Centrifugal | 100–500 ×g for 5–10 min | 70–95% |
Each seeding protocol runs inside a sterility envelope, namely laminar flow Class A or an ISO 5 cleanroom for clinical-grade work. It also carries a chain-of-custody record, so the QC team can trace any contamination back to the step that introduced it.
On the quality side, compliance is tied to measurable gates already described above: fidelity above 90%, post-print viability of at least 80% with a target above 90%, residual-DNA and GAG/collagen checks after decellularization, and sensor accuracy classes in the bioreactor. The data-integrity layer is the shared machinery of the WIA family. Control-plane messages carry a 96-bit nonce, with a 300-second skew window and a 600-second seen-nonce cache. Bioreactor telemetry uses mTLS with per-channel monotonic counters, so replayed messages are detected and dropped at the broker. Construct-lifecycle records are signed at each milestone, and the signatures are anchored into a per-batch Merkle tree so an auditor can verify provenance from seeding to release. Within the 1.x line, the standard promises that existing envelopes, endpoints and protocol exchanges stay reachable and that hosts may add optional fields but not remove existing ones.
Several practical points follow from the protocols themselves:
For a first implementation, the standard's reference container and companion CLI offer mock data for exercising the contract before real backends are connected.
The standard's own trajectory points to tighter coupling between the stages. Sensors that already report temperature, pH, dissolved oxygen, glucose and lactate can feed the next protocol directly, for example letting measured lactate and glucose decide when perfusion should change or when a construct is mature enough to implant. Printing windows could likewise be adjusted from post-print viability results. The limits are the ones the protocols already name: the diffusion range, shear stress on cells and the resolution-versus-throughput trade-off.
Phase 3 treats tissue engineering as a chain of protocols with explicit hand-offs. Printing modalities trade resolution against throughput. Bioinks must be shear-thinning gels with G' above G". Cross-linking is tuned against viability. Bioreactors supply the transport and mechanical load that each tissue needs, under PID control with defined sensor accuracy. Vascularization overcomes the 100–200 μm diffusion limit, and the seeding method sets how many cells reach the scaffold. Quality gates (fidelity, viability, residual DNA, sterility class) and signed lifecycle records make each hand-off checkable.
The next chapter turns to Phase 4, which integrates these protocol exchanges with the broader ecosystem. It covers how a laboratory's constructs, telemetry and audit records connect to other WIA family standards and to the wider systems that handle clinical and industrial production.